Whole genome or exome
A whole genome or exome sequence.
Worth, per genome
$20
How it is pricedPlanned: not collected on the platform yet.
Evidence about it (10)
- NHS patient record linked with genomic and phenotypic data, estimated market value per recordWhat health data sells for£1000–5000
- Genentech access to 23andMe genetic and phenotypic database for Parkinson's target discoveryWhat health data sells for$10 million upfront
- Sequencing one exome (cost of producing genome-level data) in the Regeneron and GSK project on UK Biobank volunteersWhat health data sells forestimated cost of $150 million if all 500,000 participants are sequenced
- Early exclusive access to UK Biobank exome sequences, price paid by each pharmaceutical company in the Regeneron-led consortium, per exomeWhat health data sells for$10 million
- UK Biobank Tier 3 data access (adds imaging, whole genome and whole exome sequence data), first three yearsWhat health data sells for£9,000
- UK Biobank whole genome sequencing project: money paid by four pharmaceutical companies, per genomeWhat health data sells for£100 million
- LunaDNA: value of a whole genome contributed by a person, paid in company sharesWhat people are paid$21
- NHS patient record linked with genomic and phenotypic data against EHR/EMR data aloneWhat makes health data worth morebetween £1000–5000 per record when combined with genomic and phenotypic data
- LunaDNA share value of a whole genome against consumer genotyping dataWhat makes health data worth more300 shares and 50 shares
- UK Biobank Tier 3 (adds imaging and sequence data) against Tier 1 (questionnaires, measurements, linked health data), first three yearsWhat makes health data worth more£3,000 and £9,000